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Summary In 31 patients with carcinoma of the breast the phenotype and activation status of tumour
infiltrating lymphocytes (TILs) was analysed by flow cytometry. The predominant cells, in all patients, were T
lymphocytes and in the majority of cases CD8+ (cytotoxic/suppressor) T lymphocytes were present in greater
numbers than CD4+ (helper) T lymphocytes. There was no relationship between the degree of lymphocytic
infiltration and either tumour stage or grade but there appeared to be an inverse correlation with the levels of
oestrogen receptor (ER) in the tumour (P<0.01). Both populations of T cells had significantly higher
numbers of cells carrying HLA DR (class II major histocompatibility antigen) than the equivalent populations
in peripheral blood from the same patient group (P<0.001). The transferrin receptor was found on similar
numbers of CD8+ T cells in peripheral blood and among the tumour infiltrating lymphocytes while more of
the CD4+ T cells infiltrating the tumour were found to carry this receptor (P=0.034). The Tac (CD25)
antigen was also on similar numbers of CD8+ T cells from both peripheral blood and the tumour but was on
fewer of the CD4+ T cells in the tumour with respect to peripheral blood (P = 0.029). In both TILs and
blood lymphocytes, the Tac antigen was consistently present on greater numbers of CD4+ T lymphocytes
than on the CD8+ T lymphocytes (P<0.001) and as this is a component of the interleukin 2 (IL-2) receptor
this may be of relevance to the use of IL-2 in TIL cancer therapy.
Tumour infiltrating lymphocytes (TILs) and in particular
their response to interleukin 2 (IL-2), have attracted con-
siderable interest in recent years because of their possible
therapeutic potential (for reviews see Oldham et al., 1989;
Rosenberg et al., 1989). It was first suggested by MacCarty
(1922), on the basis of his observations on patients with
gastric carcinoma, that lymphoid infiltration in breast
tumours was a sign of host resistance. This appeared to be
supported by the study of medullary carcinoma, which often
has a marked lymphocytic infiltrate and has a particularly
good prognosis (Moore & Foote, 1949). However, as Rich-
ardson (1956) pointed out, medullary tumours have a better
prognosis due to their poor stroma formation and reduced
ability to form metastases even when the lymphocytic infil-
trate is not present. Black (1955) and then Berg (1959) sug-
gested that mononuclear cells observed within other types of
breast carcinoma on histological section related to increased
survival and represented host resistance. These early studies
noted merely the presence or absence of lymphocytes within
the tumour and related this to long-term survival but were
unable to gain much information about the cell types in-
volved.
Studies utilising the ability of T cells to rosette sheep red
blood cells showed that T cells were the major component of
the lymphocytic infiltrate (Eremin et al., 1981; Vose et al.,
1981; Eremin et al., 1982) but were unable to further divide
the lymphocytes into functional subgroups. Since the develop-
ment of monoclonal antibodies to phenotypic markers much
work has been done in attempts to characterise the lym-
phocytic infiltration within many types of tumour. Most of
these studies have again shown that the infiltrate consists
largely of T lymphocytes with few B cells and variable
numbers of macrophages and NK cells, but there is little
agreement over further classification of the T lymphocytes
into subgroups. While some studies show a predominance of
CD4+ T cells in breast tumours (Whitwell et al., 1984;
Gotlinger et al., 1985; Horny & Horst, 1986; Ben Ezra &
Sheibani, 1987; Underwood et al., 1987; von Kleist et al.,
1987; Zuk & Walker, 1987), others showed a predominance
of CD8 + T cells (Giorno, 1983; Bhan & des Marais, 1983;
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Rowe & Beverly, 1984; Hurliman & Saraga, 1985; Bilik et al.,
1989). Taking solid tumours as a whole, most groups have
found CD8 + T cells to be in the majority (Itoh et al., 1986;
Rabinowich et al., 1987; Heo et al., 1987; Belledegrun et al.,
1988; Rosenberg et al., 1988; Durie et al., 1990).
Most of these studies were made using immunohisto-
chemical; methods with a monoclonal primary antibody to
the phenotypic surface marker and subsequent enzyme stain-
ing, predominantly peroxidase. The more recent studies (such
as that of Bilik et al., 1989) used immunofluorescent micro-
scopy with directly labelled monoclonal antibodies while Itoh
et al., Durie et al. and Rosenberg et al. used flow cytometry
to study the infiltrate found in melanoma.
Flow cytometry has several advantages; it is non-subjective
and allows a large number of cells to be analysed (5,000 per
sample in this study). The amount of fluorochrome on each
cell, as shown by the brightness of the signal, reflects the
amount of cell surface marker allowing semi-quantification.
The use of two fluorochromes simultaneously makes possible
the analysis of two coincident surface markers, in this case a
phenotypic marker and an activation marker. The use of
propidium iodide to stain the dead cells allows their
exclusion from the analysis and therefore eliminates non-
specific binding to cytoplasmic proteins. Using this method,
we have characterised the mononuclear cells infiltrating 31
breast carcinomas with regard to cell phenotype and analysed
the activation markers present on the surface of these cells.
Methods
Preparation oftumour samples
Samples of primary tumour and peripheral blood were ob-
tained from 31 consecutive patients undergoing definitive
surgery for breast carcinoma. None of these patients had
received preoperative anti-tumour therapy. Subsequently 30
of these were found to be invasive ductal carcinomas while
one patient had a lobular carcinoma.
Tumour samples were obtained aseptically at the time of
operation then the main bulk of each tumour was sent for
routine histology and the assay of tumour oestrogen recep-
tors (ER). The latter was performed using the ligand binding
method. After trimming away any fat, the tumour was
divided and one portion stored dry in liquid nitrogen. The
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rest of the tumour was mechanically disaggregated using a
scalpel and needle to tease apart the sample and release the
cells into suspension. The resultant cell suspension was har-
vested, washed, and stored in liquid nitrogen in a freezing
medium consisting of 10% dimethylsulphoxide (DMSO) and
90% fetal calf serum (FCS). The more fibrous tumours,
which did not disaggregate well and yielded poor cell suspen-
sions, were subjected to digestion overnight with collagenase
(Slocum et al., 1981; Vose, 1981; Rios et al., 1983). The
resultant cell suspension was washed and stored in freezing
medium in liquid nitrogen.
The peripheral blood, which had been collected in an
EDTA coated tube, was diluted with an equal volume of
RPMI 1640 and layered over Ficoll-Hypaque. The prepara-
tion was centrifuged at 500g for 20 min to allow density
separation of the leucocytes. The layer containing the lym-
phocytes was then harvested, washed and stored in freezing
medium in liquid nitrogen.
Preparation was carried out as soon as possible after
receipt of the samples to minimise turnover of membrane
receptors. Surface marker analysis was performed only on
cells spilled mechanically from the tumours because the
lengthy incubation in collagenase might allow changes to
occur in the membrane markers (Whiteside et al., 1986;
Miescher et al., 1988).
No attempt was made to separate the tumour infiltrating
lymphocytes (TILs) from the tumour cells as many cells
would be lost and this might distort the proportions of the
various mononuclear cells present within the infiltrate.
Immunofluorescent staining ofcellsforflow cytometry
The mononuclear cells present within the tumour and in
blood were characterised into phenotypic subgroups and
their membrane activation markers studied using two colour
immunofluorescent flow cytometry on a FACScan analyser
(Becton Dickinson). The cell samples were quickly thawed
from liquid nitrogen to avoid damage to the cells from ice
crystal formation. The cells were washed twice in filtered
phosphate buffered saline (PBS) and resuspended at a cell
density of approximately 106 cellsml'. An aliquot of 50 1l
of this cell suspension was added to each of 14 flow cyto-
metry test tubes (Falcon 2052) and incubated with the appro-
priate directly labelled monoclonal antibodies for 20 min.
Incubation was carried out in the dark to prevent bleaching
and on ice, in the presence of 0.02% w/v sodium azide, to
prevent capping and internalisation of the antibody-antigen
complex. Antibodies (Becton Dickinson, Oxford, UK) were
conjugated with either fluoroisothiocyanate (FITC) or
phycoerythrin (PE) which emit green and orange fluorescence
respectively (Table I).
Table I Monoclonal antibodies used in this study
Antibody Predominant reactivity
IgGl-FITC + IgG2a-PE Control
Leucogate Analysis of leucocyte subpopulations
(Anti-CD 45 + Anti-CD14) (Lymphocytes, monocytes,
neutrophils)
Simultest (Phenotype analysis)
Anti-Leu 2a PE CD8+ T lymphocytes
Anti-Leu 3a FITC CD4+ T lymphocytes
Anti-Leu 4 FITC T lymphocytes
Anti-Leu 12 PE B lymphocytes
Activation analysis
Anti-Leu 2a PE CD8+ T lymphocytes
Anti-Leu 3a PE CD4+ lymphocytes
Anti-HLA DR FITC HLA-DR
Anti-CD 25 FITC Interleukin 2 receptor, 55 kDa
component (Tac)
Anti-Transferrin receptor Transferrin receptor
FITC
After incubation with the fluorescent antibodies the cells
were washed and resuspended in filtered PBS. Propidium
iodide was added to each tube to a final concentration of
2figml1' to allow the identification and exclusion of dead
cells from the analysis. The cell samples were then run
through the flow cytometer and 5,000 live cells were analysed
for each sample.
Analysis
An irrelevant antibody control (goat anti-mouse IgG FITC
and goat anti-mouse IgG PE) was used to set the analysis
gates to exclude non-specific binding. Leucogate (Table I), an
antibody preparation differentially staining lymphocytes,
monocytes and neutrophils, was used to measure the propor-
tion of lymphocytes in the sample being studied. This analy-
sis was performed without any scatter gates which might
have altered the proportions of the cells measured. Then,
utilising the forward and side scatter (FSC and SSC) proper-
ties of lymphocytes in laser light, a gate was drawn around
the lymphocytes to exclude tumour cells from further analy-
sis of the tumour sample and monocytes and neutrophils
from analysis of the peripheral blood samples. Phenotypic
and activation marker analysis was performed using both the
lymphocyte and live cell gates. Macrophages and monocytes
were excluded by these gates but some NK cells fell within
them. This accounts for the null cells (non-T cells, non-B
cells) within peripheral blood.
The relative proportions of the phenotypic subsets were
measured using four-quadrant analysis while activation mar-
kers were measured by isolating the phenotype under study
on the instrument and using histogram analysis. The analysis
gate for positive cells was based on the goat anti-mouse
control for non-specific staining. Preparations of anti-Leu 4
FITC/anti-Leul2 PE and anti-Leu3a FITC/anti-Leu2a PE
allowed the lymphocytes to be phenotyped as T cells, B cells,
CD4+ (helper) T cells, or CD8+ (cytotoxic/suppressor) T
cells.
The activation markers studied were HLA DR, the class II
major histocompatibility antigen, Tac (CD-25) the 55 kDa
component of the interleukin-2 receptor, and the transferrin
receptor. Double staining techniques with PE conjugated
phenotypic antibodies and FITC conjugated activation mar-
ker antibodies demonstrated the proportion of CD4+ T cells
and CD8+ T cells bearing these markers.
Statistical analysis, where appropriate, was by the Wil-
coxon signed rank test. Tumour grading was by the method
of Bloom and Richardson (1957).
Results
The patient group studied is shown in Table II. Nine of the
tumours contained too few lymphocytes to permit study of
their activation markers with four having too small an infil-
trate even for phenotyping. The lymphocytic infiltrate ranged
from less than 1% of the cells harvested to 83% with a mean
of 10.5%. This did not correlate with tumour stage or histo-
logical grade but there was an inverse correlation between the
severity of lymphocytic infiltration and the levels of ER in
the tumour (P<0.01) (Figure 1). In line with the results of
the majority of other groups, we found the tumour infiltrate
to consist largely of T cells with only one tumour containing
a significant number of B cells (Figure 2). This was also the
tumour with the largest lymphocytic infiltrate but no trend
was seen among the other tumours. When the T cells were
further subdivided, the CD8+ population was found to
predominate, though in seven tumours the CD4+ T cells
were present in greater numbers (Figure 3).
The CD4+/CD8+ ratio ranged from 0.2 to 2.1 with an
average of 0.8, which was a reversal of that in peripheral
blood, where the CD4+/CD8+ ratios ranged from 0.8 to
5.0 with an average of 1.7.
Among the activation markers, HLA DR (Figure 4) was
present on many more of both CD8+ T cells (average 57%)TIL IN BREAST CANCER 973
Table II Patient data
Grade
II
III
III
II
II
I
II
II
I
II
II
I
III
III
Lobular
II
III
II
III
II
I
II
II
II
II
II
I
III
III
Stage
II
I
I
I
II
II
II
II
I
II
II
I
I
I
I
II
II
I
II
II
II
II
I
II
I
I
II II
Nodal involvement
(no. invadedl
n. examined)
1/8
0/11
0/4
0/9
1/9
1/6
2/9
2/13
0/6
8/8
2/5
0/3
0/11
0/16
0/9
2/6
2/14
0/3
13/13
0/5
2/11
9/9
11/11
0/12
0/9
0/16
2/12
0/9
0/14
3/17
1/5
ER
(fmolper mg
protein)
299
358
10
13
86
12
118
0
126
102
73
224
250
0
10
0
19
n.a.
10
0
0
30
40
28
22
187
94
73
0
0
19
and CD4+ T cells (average 49%) within the tumour than in
the PBLs. In the latter the average values were 36% of the
CD8+ T cells and 20% of the CD4+ T cells (P<0.001).
In the case of the transferrin receptor (Figure 5), the
numbers of CD8+ T cells within the tumour bearing this
marker (average 39%) were not significantly higher than the
numbers in blood (average 38%). This receptor was present
on more of the CD4+ T cells in the tumour (average 48%)
than in the blood (average 35%) (P= 0.034).
A different trend was observed with the Tac antigen
(Figure 6) which was present on similar numbers of CD8 + T
cells in both the infiltrate (average 14%) and in blood
(average 16%) but tended to be on fewer CD4+ T cells in
the infiltrate (average 27.5%) than in blood (average 33%)
(P = 0.029).
It is particularly noteworthy that this component of the
I1-2 receptor was consistently found on more CD4+ T cells
than CD8 + T cells in both tumour infiltrating and peri-
pheral blood lymphocytes (P<0.001).
100-
80-
60
* % TILs
40
20-
0.
0 0 0 0 0 0012 19 19 19 28 40 73 94 118 187 250 358
13 19 19 22 30 73 86 102 126 224 299
ER (fmol mg-' protein)
Figure 1 Levels of ER in tumours related to the degree of
lymphocytic infiltration (in ascending order).
80
* %T M%B
60
0
20
4 5 6 7 810 12 14 16 18 20 22 24 26 28 30 11 13 15 17 19 21 23 25 27 29 31
Patient code
Figure 2 Levels of B and T cells in tumour infiltrating lym-
phocytes (in ascending order). Average values from peripheral
blood from the same patient group were 60% T cells and 13% B
cells.
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Figure 3 Levels of CD4+ and CD8+ T cells in tumour infil-
trating lymphocytes (in ascending order).
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Figure 4 Percentage of tumour infiltrating lymphocytes bearing
HLA DR. Corresponding levels on peripheral blood from the
same patient group averaged 20% on CD4 + T lymphocytes and
36% on CD8 + T lymphocytes.
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Figure 5 Percemtage of tumour infiltrating lymphocytes bearing
the transferrin receptor. Corresponding levels on peripheral blood
lymphocytes from the same patient group averaged 35% on
CD4+ T lymphocytes and 38% on CD8+ T lymphocytes.
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Figure 6 Percentage of tumour infiltrating lymphocytes bearing
Tac (CD 25). Corresponding levels on peripheral blood lym-
phocytes from the same patient group averaged 33% on CD4+
T lymphocytes and 16% on CD8 + T lymphocytes.
Discussion
From these results it can be seen that about 60% of the
tumours studied had a detectable lymphocytic infiltrate with
the maximum infiltrate accounting for more than 80% of the
cells harvested from the tumour. The degree of lymphocytic
infiltrate was not related to tumour stage or histological
grade but showed an inverse correlation with the level of ER
found within the tumour, the ER negative tumours showing
the greatest infiltration by lymphocytes. This is similar to the
findings of An et al. (1987) who looked at the relationship
between mononuclear infiltrate and the presence of oestrogen
receptors using immunohistological methods and also found
an inverse correlation. Underwood et al. (1987) did not find a
significant correlation between T lymphocyte infiltration and
lack of ER but this trend can be seen in their results and the
lack of statistical significance may be due to the smaller
number of patients studied. Although there is no clear rela-
tionship to histological grade, the above results suggest that a
lymphocytic reaction within tumours may in some way be
related to poor differentiation. It is of note that the highest
ratio of lymphocytes to tumour cells was 5/1, calling into
question the use, in cytotoxicity assays, of effector/target
ratios of 50/1.
CD8+ T cells predominated in most tumours. This is in
agreement with the previous work by Giorno (1983), Rowe
and Beverly (1984), Bilik et al. (1989) and others, although at
odds with the findings of such groups as Horny and Horst
(1986), Underwood et al. (1987) and von Kleist et al. (1987).
The wide variation in phenotype proportions found witalin
tumours may reflect the different methods used. As iost
groups have used tissue sections stained with monocional
antibodies to the phenotype markers, using either an enzyme
or fluorochrome conjugate, it is possible that sample varia-
bility can play a part in giving such a variety of results. This
is particularly important in view of tumour heterogeneity
(Edwards, 1985) and may be avoided to some degree by
processing larger amounts of tumour. By virtue of its ability
to give data on 5,000 live cells, flow cytometry can make
more statistically secure observations without introducing
observer error. The use of propidium iodide to exclude dead
cells from the analysis avoids non-specific cytoplasmic stain-
ing which can be mistaken for membrane staining in cells
with a large nucleus and little cytoplasm. The advantage of
staining tissue sections, which is lost in flow cytometry, is
that the relationship of tumour infiltrating lymphocytes to
the overall architecture of the tumour can be investigated.
A considerable advantage of flow cytometry is that it
makes it possible to carry out accurate double staining
experiments, allowing the detection of the cell surface activa-
tion markers as carried by the two phenotypes.
HLA DR is a marker of T cell activation and is known to
be related to antigen presentation in B cells and macrophages
although its precise role on T cells is less clear. It is present
on far greater numbers of TILs than on the peripheral blood
lymphocytes suggesting that both types of T cell within the
infiltrate are activated with respect to this marker although it
is present on a greater proportion of the CD8+ T cells.
Increased levels of transferrin receptor on the membrane of
a cell suggests that it is preparing for division at which time
the iron requirement increases because of the increased
requirement for ribonucleotide reductase. While there is no
difference between the number of CD8 + T cells carrying this
marker in peripheral blood and the infiltrate, there is a
greater number of CD4+T cells carrying this marker in the
infiltrate suggesting some increase in the number ofdividing cells in this subgroup. In the case of the Tac antigen there is
again no difference in the proportion of CD8 + T cells
carrying this receptor in the infiltrate or in peripheral blood
but there are fewer CD4+ T cells bearing this marker with
respect to peripheral blood.
Consistently greater numbers ofCD4+ rather than CD8 +
T cells bear this marker, whether in blood or in the tumour
infiltrate. Tsudo et al. (1986) and Robb et al. (1987) have
demonstrated that the 11-2 receptor has two components, one
at 55 kDa, and the other, which carries the signal transduc-
tion mechanism, at 75 kDa (reviewed by Smith, 1989). Cells
bearing the II-2 receptor may have one of three variations,
55/55, 75/75 or 75/55 the last of which is the high affinity
receptor. Thus it might be that CD4+ T cells are intrin-
sically different from CD8 + T cells and carry the 55/55
receptor rather than the 75/55 high affinity receptor. As Tac
(CD-25) is the 55 kDa part of the 11-2 receptor, this would
give the incorrect impression of the CD4+ T cells carrying
more functional II-2 receptor. If both T cell subsets- are
constitutionally similar and carry the same type of 11-2
receptor then these results show a quantitative rather than
qualitative, difference between the two cell types. This inter-
pretation is supported by the finding that, in long-term 11-2
cultures, the CD4+ (helper) subpopulation appears to be
selectively expanded over the CD8+ (cytotoxic/suppressor)
population and thus the cells being returned to the patient as
TIL therapy are predominantly of the helper phenotype
(Rosenberget al. 1988; Belldegrun et al., 1988). As TIL
therapy has shown some striking responses, the question of
how this is mediated requires to be clarified.
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